The fast-growing field of precision medicine aims to follow through on the potential of personalization and data aggregation technologies in an era of smarter healthcare. Its purpose is twofold: to better understand the mechanisms of disease, and to promote more modern and equitable approaches to care.
Here in California, precision medicine has received a surge of adrenaline from the California Initiative to Advance Precision Medicine (CIAPM), a program launched in 2015. CIAPM has seen to completion eight innovative, collaborative translational research projects all over the state from a variety of private and public institutions, awarding over $11 million in support to explore fascinating ideas and make important and useful discoveries.
The Challenge of AKU
Alkaptonuria, or AKU, is a rare and less-studied inherited metabolic disorder. It results from a deficiency of homogentisic acid dioxygenase (HGD), part of the tyrosine degradation pathway. As of yet, there is no cure. However, The National Centre for Alkaptonuria, hosted by The Royal Liverpool and Broadgreen University Hospitals, is supporting international clinical trials that may help change that. And clinical chemist Joseph Taylor says that Volumetric Absorptive Microsampling (VAMS®) technology and Mitra® devices already play an important role in the relevant drug development process.
Great science and smarter healthcare need better blood collection and stronger support. That’s the ideas behind the VAMS® Incubator Program, a powerful new resource for blood collection innovators in the worlds of healthcare, science, and research.
Medical technology, also known as "healthtech" or "medtech," manifests in a wide range of products tailored for smarter healthcare for the human population. The innovation of these technologies is meant to improve the delivery of healthcare in a number of ways.
At the 2019 meeting of the American Transplant Congress, held this year in Boston, scientists from the Oslo University Hospital, Rikshospitalet presented exciting findings regarding more patient-centered AUC-monitoring of tacrolimus, a cornerstone immunosppressant, using blood microsampling systems driven by Mitra® devices and Volumetric Absorptive Microsampling (VAMS™) technology. Researcher and PhD student Marte Theie Gustavsen was on hand to give the presentation and made time to answer a few questions.
The cannabis industry has recently become big business. In 2018, according to Consumer Reports, for the first time in history, the cannabis industry is worth $10 billion. The implications of cannabis testing results continue to gain importance and we need to find innovative methods of testing for cannabis.